Immunohistochemical detection of dopamine D2 receptors in human pituitary adenomas
- PMID: 21071344
- DOI: 10.2478/v10042-010-0031-1
Immunohistochemical detection of dopamine D2 receptors in human pituitary adenomas
Abstract
Thirty one pituitary adenomas and 3 samples of peritumoral anterior pituitary tissue were immunostained with an antibody raised against dopamine D2 receptor protein. The positive reactions were found in cell cytoplasm, a subpopulation of cell nuclei and the intratumoral blood vessels walls. As expected, the positive immunostaining was shown in cytoplasm and/or cell nuclei of all examined prolactinomas (7/7). In acromegaly the positive D2 staining occurred in 5/7 samples, in gonadotropinomas in 6/8 and in plurihormonal adenomas 2/4. The lowest expression was observed in corticotropinomas (1/5). These findings corroborate with the well known efficacy of D2 agonists in the treatment of prolactinomas and somatotropinomas, and support the rationale of the therapeutic trials with these compounds in gonadotropinomas. Moreover, the presence of D2 receptors in intratumoral blood vessels walls constitutes the possibility of the anti-angiogenic action of D2 agonists in pituitary adenomas.
Similar articles
-
Immunohistochemical detection of PPARgamma receptors in the human pituitary adenomas: correlation with PCNA.Folia Histochem Cytobiol. 2005;43(3):137-41. Folia Histochem Cytobiol. 2005. PMID: 16201313
-
p75 and TrkC neurotrophin receptors demonstrate a different immunoreactivity profile in comparison to TrkA and TrkB receptors in human normal pituitary gland and adenomas.Neuroendocrinology. 2008;88(2):127-34. doi: 10.1159/000119743. Epub 2008 Mar 5. Neuroendocrinology. 2008. PMID: 18319596
-
Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.J Nucl Med. 1996 Dec;37(12):1931-7. J Nucl Med. 1996. PMID: 8970508
-
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.Front Endocrinol (Lausanne). 2022 Jan 12;12:791633. doi: 10.3389/fendo.2021.791633. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35095761 Free PMC article. Review.
-
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.Mol Cell Endocrinol. 2008 May 14;286(1-2):206-13. doi: 10.1016/j.mce.2007.12.008. Epub 2007 Dec 23. Mol Cell Endocrinol. 2008. PMID: 18241980 Review.
Cited by
-
Dopamine agonist-responsive Cushing's disease.BMJ Case Rep. 2019 Feb 13;12(2):e228045. doi: 10.1136/bcr-2018-228045. BMJ Case Rep. 2019. PMID: 30765454 Free PMC article.
-
Somatostatin and Somatostatin Receptors in Tumour Biology.Int J Mol Sci. 2023 Dec 28;25(1):436. doi: 10.3390/ijms25010436. Int J Mol Sci. 2023. PMID: 38203605 Free PMC article. Review.
-
The dopaminergic control of Cushing's syndrome.J Endocrinol Invest. 2022 Jul;45(7):1297-1315. doi: 10.1007/s40618-021-01661-x. Epub 2022 Apr 23. J Endocrinol Invest. 2022. PMID: 35460460 Free PMC article. Review.
-
Dopamine Agonists for Pituitary Adenomas.Front Endocrinol (Lausanne). 2018 Aug 21;9:469. doi: 10.3389/fendo.2018.00469. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30186234 Free PMC article. Review.
-
Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.Acta Endocrinol (Buchar). 2021 Jul-Sep;17(3):377-382. doi: 10.4183/aeb.2021.377. Acta Endocrinol (Buchar). 2021. PMID: 35342478 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials